Suppr超能文献

鉴定新型 N-(吗啉-4-羰基)脒类化合物作为抗丙型肝炎病毒复制的有效抑制剂。

Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication.

机构信息

Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.

出版信息

Antimicrob Agents Chemother. 2012 Mar;56(3):1315-23. doi: 10.1128/AAC.05764-11. Epub 2011 Dec 27.

Abstract

To identify novel compounds that possess antiviral activity against hepatitis C virus (HCV), we screened a library of small molecules with various amounts of structural diversity using an HCV replicon-expressing cell line and performed additional validations using the HCV-JFH1 infectious-virus cell culture. Of 4,004 chemical compounds, we identified 4 novel compounds that suppressed HCV replication with 50% effective concentrations of ranging from 0.36 to 4.81 μM. N'-(Morpholine-4-carbonyloxy)-2-(naphthalen-1-yl) acetimidamide (MCNA) was the most potent and also produced a small synergistic effect when used in combination with alpha interferon. Structure-activity relationship (SAR) analyses revealed 4 derivative compounds with antiviral activity. Further SAR analyses revealed that the N-(morpholine-4-carbonyloxy) amidine moiety was a key structural element for antiviral activity. Treatment of cells with MCNA activated nuclear factor κB and downstream gene expression. In conclusion, N-(morpholine-4-carbonyloxy) amidine and other related morpholine compounds specifically suppressed HCV replication and may have potential as novel chemotherapeutic agents.

摘要

为了鉴定具有抗丙型肝炎病毒(HCV)活性的新型化合物,我们使用表达 HCV 复制子的细胞系筛选了具有不同结构多样性的小分子文库,并使用 HCV-JFH1 感染性病毒细胞培养物进行了额外的验证。在 4004 种化合物中,我们鉴定出了 4 种新型化合物,它们对 HCV 复制的抑制作用在 50%有效浓度范围内从 0.36 到 4.81 μM。N'-(吗啉-4-羰基氧基)-2-(萘-1-基)乙酰胺(MCNA)是最有效的化合物,与α干扰素联合使用时还产生了较小的协同作用。构效关系(SAR)分析显示,有 4 种具有抗病毒活性的衍生化合物。进一步的 SAR 分析表明,N-(吗啉-4-羰基氧基)脒基部分是抗病毒活性的关键结构要素。MCNA 处理细胞会激活核因子 κB 和下游基因表达。总之,N-(吗啉-4-羰基氧基)脒基和其他相关吗啉化合物特异性地抑制 HCV 复制,可能具有作为新型化学治疗剂的潜力。

相似文献

1
Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication.
Antimicrob Agents Chemother. 2012 Mar;56(3):1315-23. doi: 10.1128/AAC.05764-11. Epub 2011 Dec 27.
2
Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection.
Antimicrob Agents Chemother. 2011 Jun;55(6):2537-45. doi: 10.1128/AAC.01780-10. Epub 2011 Mar 28.
3
Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets.
J Virol. 2007 Mar;81(6):3005-8. doi: 10.1128/JVI.02083-06. Epub 2006 Dec 20.
4
5
Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.
J Viral Hepat. 2009 Jul;16(7):506-12. doi: 10.1111/j.1365-2893.2009.01102.x. Epub 2009 Mar 3.
6
8
Inhibition of hepatitis C virus replication by arsenic trioxide.
Antimicrob Agents Chemother. 2004 Aug;48(8):2876-82. doi: 10.1128/AAC.48.8.2876-2882.2004.
9
Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
J Clin Microbiol. 2005 Nov;43(11):5679-84. doi: 10.1128/JCM.43.11.5679-5684.2005.
10
Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds.
Antimicrob Agents Chemother. 2014;58(2):995-1004. doi: 10.1128/AAC.02094-13. Epub 2013 Nov 25.

引用本文的文献

2
CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses.
J Clin Invest. 2014 Aug;124(8):3479-88. doi: 10.1172/JCI73805. Epub 2014 Jul 8.
3
Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus.
PLoS One. 2013 Dec 17;8(12):e82299. doi: 10.1371/journal.pone.0082299. eCollection 2013.

本文引用的文献

2
Boceprevir for untreated chronic HCV genotype 1 infection.
N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.
4
Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.
Virology. 2010 Sep 30;405(2):361-9. doi: 10.1016/j.virol.2010.06.020. Epub 2010 Jul 6.
5
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
Gastroenterology. 2010 Feb;138(2):447-62. doi: 10.1053/j.gastro.2009.11.055. Epub 2009 Dec 16.
6
Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
Bioorg Med Chem Lett. 2009 Oct 15;19(20):5898-901. doi: 10.1016/j.bmcl.2009.08.069. Epub 2009 Aug 21.
7
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication.
Cell Host Microbe. 2009 Mar 19;5(3):298-307. doi: 10.1016/j.chom.2009.02.001.
9
Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen.
Antimicrob Agents Chemother. 2007 Oct;51(10):3756-9. doi: 10.1128/AAC.00233-07. Epub 2007 Aug 6.
10
Bone morphogenetic protein-7 and interferon-alpha synergistically suppress hepatitis C virus replicon.
Biochem Biophys Res Commun. 2007 Jun 1;357(2):467-73. doi: 10.1016/j.bbrc.2007.03.167. Epub 2007 Apr 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验